MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

80.84
+4.25
+5.55%
After Hours: 80.84 0 0.00% 16:08 12/06 EST
OPEN
76.18
PREV CLOSE
76.59
HIGH
81.26
LOW
73.41
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
159.54
52 WEEK LOW
73.41
MARKET CAP
13.93B
P/E (TTM)
-16.2398
1D
5D
1M
3M
1Y
5Y
Here’s Why Exact Sciences (EXAS) Landed in RiverPark’s Detractor List
RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. The RiverPark Large Growth Fund (the “Fund”) returned -3.23% for the third quarter of 2...
Insider Monkey · 3d ago
Why Is Exact Sciences (EXAS) Down 14.9% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 4d ago
Zacks Market Edge Highlights: Lululemon, Exact Sciences, Pinterest, PayPal and Shopify
Zacks Market Edge Highlights: Lululemon, Exact Sciences, Pinterest, PayPal and Shopify
Zacks · 4d ago
Exact Sciences Highlights Publication Of New England Journal Of Medicine Confirms Women With Node-Positive, Early-Stage Breast Cancer Can Avoid Chemo With Oncotype DX Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led · 4d ago
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine.i The study, led by the independent SWOG Cancer Resear...
PR Newswire · 4d ago
Growth Stock Sell-Off: What Should You Do?
Zacks.com · 5d ago
Bioscience nonprofit spurs $658M economic impact on Arizona, report says
The Translational Genomics Research Institute, a nonprofit that has spun off numerous bioscience startups over the years, had a 2020 economic impact that was more than triple that of 2017, according to a new report. Here's what's behind that impact.
American City Business Journals · 6d ago
Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test
Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal cancer screening test to health care providers.
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXAS. Analyze the recent business situations of EXACT Sci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

47.37%Strong Buy
42.11%Buy
10.53%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EXAS stock price target is 132.53 with a high estimate of 161.00 and a low estimate of 95.00.
High161.00
Average132.53
Low95.00
Current 80.84
EPS
Actual
Estimate
-2.23-1.67-1.12-0.56
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 818
Institutional Holdings: 176.47M
% Owned: 102.41%
Shares Outstanding: 172.32M
TypeInstitutionsShares
Increased
239
12.28M
New
52
473.34K
Decreased
168
7.76M
Sold Out
67
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.95%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President
Ana Hooker
Chief Scientific Officer
Graham Lidgard
General Manager
Jake Orville
General Manager
Gisela Paulsen
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Shacey Petrovic
Independent Director
Kathleen Sebelius
Independent Director
Katherine Zanotti
No Data
About EXAS
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.